Research Article

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Figure 1

Aggregate pharmacodynamic responses to ganetespib and sirolimus therapy.